3 January 2025 in Cell Death & Differentiation
29 July 2025 in Advanced Science
Hepatocellular carcinoma (HCC) is a common malignant tumor. However, the role of lactic acid–modified proteins in its pathogenesis is unclear. This study determines the distribution of a novel post‐translational modification—protein lactylation—in HCC to identify potential targets and obtain mechanistic insights into this disease. Using high‐throughput proteomics, lysine 312 lactylation (K312‐lac) of the Set1/Ash2 histone methyltransferase complex subunit (ASH2L) is revealed as a candidate for further investigation. Subsequently, alanyl‐tRNA synthetase 1 (AARS1) and histone deacetylase 1 (HDAC1) are shown to mediate lactylation modification of ASH2L. In vivo experiments demonstrate that ASH2L‐K312‐lac promotes HCC malignant progression and is positively correlated with tumor microvessel density, and vascular endothelial growth factor A (VEGFA) is identified as the key mediator in ASH2L‐K312‐lac‐induced angiogenesis. High‐throughput sequencing reveals ASH2L‐K312‐lac enrichment in the genome regions encoding VEGFA , facilitating targeted recruitment of the mixed lineage leukemia complex to these loci and enhancing VEGFA expression through synergistic activation of enhancers and promoters. Finally, clinical sample analyses and robust in vivo preclinical experiments identify ASH2L‐K312‐lac as a promising therapeutic target for clinical application. These findings provide a theoretical foundation for the clinical translation of ASH2L‐K312‐lac‐based treatment approaches, offering potential advancements in HCC diagnosis and treatment.
29 August 2025 in Oncogene
12 November 2024 in Advanced Science
Hepatocellular carcinoma (HCC) is characterized by frequent intrahepatic and distant metastases, resulting in a poor prognosis for patients. Epithelial–mesenchymal transition (EMT) plays a pivotal role in this process. However, the expression of NOP2/Sun RNA methyltransferase 5 (NSUN5) in HCC and its role in mediating EMT remain poorly understood. In this study, clinicopathological analyses are conducted across multiple independent HCC cohorts and induced tumor formation in Nsun5‐knockout mice. The findings reveal an upregulation of NSUN5 expression in tumor tissues; conversely, the absence of Nsun5 hinders the malignant progression of HCC, indicating that NSUN5 may serve as a significant oncogene in HCC. Furthermore, elevated levels of NSUN5 enhance EMT processes within HCC cells. NSUN5‐knockout cells exhibit reduced invasion and migration capabilities under both in vivo and in vitro conditions, while overexpression of NSUN5 yields opposing effects. Mechanistically, high levels of NSUN5 promote the enrichment of trimethylated histone H3 at lysine 4 (H3K4me3) at the promoter region of SMAD3 through recruitment of the WDR5, thereby facilitating HCC metastasis via SMAD3‐mediated EMT pathways. Collectively, this study identifies NSUN5 as a novel driver of metastasis in HCC and provides a theoretical foundation for potential therapeutic strategies against this malignancy.
26 August 2024 in Oncogene
1 August 2022 in Cancer Science
Although angiogenesis is a critical event in hepatocellular carcinoma (HCC), and this process provides the tumor with sufficient oxygen and nutrients, the precise molecular mechanism by which it occurs is not fully understood. NEDD4 binding protein 3 (N4BP3) was identified in this study as a novel pro‐angiogenic factor in HCC cell lines and tissues. We discovered that N4BP3 was significantly expressed in HCC and that its level of expression was positively correlated with the density of tumor microvessels in HCC tissues. Cell biology experiments have shown that N4BP3 knockdown in HCC cells significantly inhibits the formation of complete tubular structures by HUVECs in vitro and HCC angiogenesis in vivo. In HCC cells, overexpression of N4BP3 has the opposite effects. Further cell and molecular biology experiments have revealed that N4BP3 interacts with KAT2B (lysine acetyltransferase 2B), increasing signal transducer and activator of transcription 3 (STAT3) expression by regulating the distribution of acetyl‐histone H3 (Lys27) (H3K27ac) in its promoter region. This, in addition, regulates the activity of the STAT3 signaling pathway, which promotes the proliferation of microvessels in HCC and accelerates the malignant process of the tumor. In vivo experiments in nude mice have confirmed our findings, and also suggested that N4BP3 could be a potential target for the treatment of HCC in combination with sorafenib.